Zobrazeno 1 - 10
of 771
pro vyhledávání: '"David A. Hyman"'
Autor:
David A. Hyman
'Drawing on an unusually rich trove of data, the authors have refuted more politically convenient myths in one book than most academics do in a lifetime.'—Nicholas Bagley, professor of law, University of Michigan Law School'Synthesizing decades of
Autor:
Tripti Shrestha Bhattarai, Tambudzai Shamu, Alexander N. Gorelick, Matthew T. Chang, Debyani Chakravarty, Elena I. Gavrila, Mark T. A. Donoghue, JianJong Gao, Swati Patel, Sizhi Paul Gao, Margaret H. Reynolds, Sarah M. Phillips, Tara Soumerai, Wassim Abida, David M. Hyman, Alison M. Schram, David B. Solit, Lillian M. Smyth, Barry S. Taylor
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-11 (2022)
How different oncogenic Akt mutants can affect the response to Akt inhibitors is currently unclear. Here, the authors analyse somatic mutations of Akt1-3 isoforms in several human cancers, investigate their oncogenic effects and therapeutic relevance
Externí odkaz:
https://doaj.org/article/2f4ee7e6727f4b59871619d4a10453d0
Autor:
Ezra Y. Rosen, Helen H. Won, Youyun Zheng, Emiliano Cocco, Duygu Selcuklu, Yixiao Gong, Noah D. Friedman, Ino de Bruijn, Onur Sumer, Craig M. Bielski, Casey Savin, Caitlin Bourque, Christina Falcon, Nikeysha Clarke, Xiaohong Jing, Fanli Meng, Catherine Zimel, Sophie Shifman, Srusthi Kittane, Fan Wu, Marc Ladanyi, Kevin Ebata, Jennifer Kherani, Barbara J. Brandhuber, James Fagin, Eric J. Sherman, Natasha Rekhtman, Michael F. Berger, Maurizio Scaltriti, David M. Hyman, Barry S. Taylor, Alexander Drilon
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)
The results of the phase 1/2 LIBRETTO-001 clinical trial has recently established the efficacy of the RET inhibitor selpercatinib in RET-driven cancers. Here, the authors characterize the molecular determinants of response and resistance in 72 LIBRET
Externí odkaz:
https://doaj.org/article/c9aadc1f6bbc44acba731c2a7dcb7aef
Autor:
Lillian M. Smyth, Gerald Batist, Funda Meric-Bernstam, Peter Kabos, Iben Spanggaard, Ana Lluch, Komal Jhaveri, Andrea Varga, Andrea Wong, Alison M. Schram, Helen Ambrose, T. Hedley Carr, Elza C. de Bruin, Carolina Salinas-Souza, Andrew Foxley, Joana Hauser, Justin P. O. Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Myria Nikolaou, Gaia Schiavon, Pedram Razavi, Udai Banerji, José Baselga, David M. Hyman, Sarat Chandarlapaty
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-7 (2021)
Abstract Five to ten percent of ER+ metastatic breast cancer (MBC) tumors harbor somatic PTEN mutations. Loss of function of this tumor-suppressor gene defines a highly aggressive, treatment-refractory disease for which new therapies are urgently nee
Externí odkaz:
https://doaj.org/article/97cb292e26054c75a968bad21fc37c9b
Autor:
Ezra Y. Rosen, Helen H. Won, Youyun Zheng, Emiliano Cocco, Duygu Selcuklu, Yixiao Gong, Noah D. Friedman, Ino de Bruijn, Onur Sumer, Craig M. Bielski, Casey Savin, Caitlin Bourque, Christina Falcon, Nikeysha Clarke, Xiaohong Jing, Fanli Meng, Catherine Zimel, Sophie Shifman, Srushti Kittane, Fan Wu, Marc Ladanyi, Kevin Ebata, Jennifer Kherani, Barbara J. Brandhuber, James Fagin, Eric J. Sherman, Natasha Rekhtman, Michael F. Berger, Maurizio Scaltriti, David M. Hyman, Barry S. Taylor, Alexander Drilon
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/5da51ab03db947f7a3ffd0a6118bb43a
Autor:
Loredana Puca, Michele S. Dowless, Carmen M. Perez-Ferreiro, Maria Jesus Ortiz-Ruiz, Gregory P. Donoho, Andrew Capen, Lysiane Huber, Sarah M. Bogner, Dongling Fei, Jason R. Manro, Chun Ping Yu, Wei Guo Xu, Rui Wang, Shuang Chen, Mark A. Hicks, Parisa Zolfaghari, Andrew Faber, Raymond Gilmour, Monica D. Ramstetter, Matthew T. Chang, Maria Jose Lallena, Xuequian Gong, David M. Hyman, Lillian M. Smyth, Barbara J. Brandhuber, Barry S. Taylor, Anke Klippel
Publikováno v:
Cancer Research. 83:P4-08
Background Phosphoinositide 3-kinase alpha (PI3Kα) H1047R mutations are activating oncogenic events that occur in ~15% of breast cancers (BC). Early generation PI3Kα inhibitors target both wild-type (WT) and mutant PI3Kα and, as a result, their ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::527fc9e133f9687e3e79e24c582b9519
https://doi.org/10.1158/1538-7445.sabcs22-p4-08-02
https://doi.org/10.1158/1538-7445.sabcs22-p4-08-02
Publikováno v:
Journal of Empirical Legal Studies. 19:897-935
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5dadec300164c3b0cfa380f3fb24b040
https://doi.org/10.1111/jels.12338
https://doi.org/10.1111/jels.12338
Autor:
Maurizio Scaltriti, Charles M. Rudin, Neal Rosen, Elisa de Stanchina, Gary A. Ulaner, Junji Tsurutani, Ronglai Shen, John T. Poirier, Mark G. Kris, Maria E. Arcila, Pedram Razavi, Jorge S. Reis-Filho, Vicky Makker, Alan L. Ho, Darren J. Buonocore, Jason S. Lewis, David M. Hyman, Fabiola Cecchi, Anuja Bhalkikar, Wei-Li Liao, Sheeno Thyparambil, Helena A. Yu, David R. Jones, James M. Isbell, Michael Offin, Tony Ng, Paul R. Barber, Michael F. Berger, David B. Solit, Nancy U. Lin, Rachel A. Freedman, Irmina Diala, Alshad S. Lalani, Clare J. Wilhem, Gregory Weitsman, Besnik Qeriqi, Megan Little, Inna Khodos, Marissa Mattar, Chongrui Xu, Mackenzie L. Myers, Hai-Yan Tu, Sophie Shifman, Yanyan Cai, Laura Baldino, Emiliano Cocco, Sandra Misale, Flavia Michelini, Bob T. Li
Supplementary Fig 6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3be34c1b193827111ba4ed9bb0d011a7
https://doi.org/10.1158/2159-8290.22535611
https://doi.org/10.1158/2159-8290.22535611
Autor:
Nikolaus Schultz, David B. Solit, Barry S. Taylor, Laura Tang, Michael F. Berger, David H. Ilson, Neal Rosen, Marc Ladanyi, Maurizio Scaltriti, David M. Hyman, Ahmet Zehir, Sumit Middha, Marinela Capanu, Mark E. Robson, Jinru Shia, Daniela Molena, David R. Jones, Valerie W. Rusch, Zsofia K. Stadler, Manjit Bains, Daniel G. Coit, Hans Gerdes, Mark Schattner, Vivian E. Strong, Liying Zhang, David P. Kelsen, Benjamin E. Gross, Zachary J. Heins, Jianjiong Gao, Efsevia Vakiani, Nancy Bouvier, Ritika Kundra, Yaelle Tuvy, Jamie C. Riches, Geoffrey Y. Ku, Jaclyn F. Hechtman, Walid K. Chatila, Philip Jonsson, Francisco Sanchez-Vega, Yelena Y. Janjigian
The incidence of esophagogastric cancer is rapidly rising, but only a minority of patients derive durable benefit from current therapies. Chemotherapy as well as anti-HER2 and PD-1 antibodies are standard treatments. To identify predictive biomarkers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ced1fa93e0e6dc6dca9d2d543eb706b
https://doi.org/10.1158/2159-8290.c.6546998.v1
https://doi.org/10.1158/2159-8290.c.6546998.v1
Autor:
Hongxin Zhang, Ahmet Zehir, Emily Yu, Thomas V. Yu, Celeste Yu, Stuart Watt, Chetna Wathoo, Lucy L. Wang, Emile E. Voest, Carl Virtanen, Victor E. Velculescu, Harm van Tinteren, Tony van de Velde, Laura J. Van 'T Veer, Eliezer M. Van Allen, Stacy B. Thomas, Jelle J. ten Hoeve, Barry S. Taylor, Shawn M. Sweeney, Thomas P. Stricker, Natalie H. Stickle, Parin Sripakdeevong, Jean Charles Soria, Gabe S. Sonke, David B. Solit, Lillian L. Siu, Priyanka Shivdasani, Kenna R Mills Shaw, Nikolaus Schultz, Deborah Schrag, Charles L. Sawyers, Mark J. Routbort, Barrett J. Rollins, Brendan Reardon, Trevor J. Pugh, Ben Ho Park, John A. Orechia, Larsson Omberg, Petra M. Nederlof, Nathanael D. Moore, Gordon Mills, Clinton Miller, Christine M. Micheel, Funda Meric-Bernstam, Gerrit A. Meijer, David S. Maxwell, Ian Maurer, Laura E. MacConaill, Zhibin Lu, David Liu, James Lindsay, Neal I. Lindeman, Mia A. Levy, Eva M. Lepisto, Michele L. LeNoue-Newton, Céline Lefebvre, Marc Ladanyi, Ritika Kundra, Priti Kumari, Walter Kinyua, Cyriac Kandoth, Suzanne Kamel-Reid, David M. Hyman, Jan Hudeček, Hugo Horlings, Stephanie Hintzen, Zachary J. Heins, Justin Guinney, Benjamin E. Gross, Christopher D. Gocke, Stu Gardos, Francisco Garcia, Jianjiong Gao, P. Andrew Futreal, Matthew D. Ducar, Raymond N. DuBois, Semih Dogan, Catherine Del Vecchio Fitz, Nancy E. Davidson, Kristen K. Dang, Debyani Chakravarty, Ethan Cerami, Fabien Calvo, Mariska Bierkens, Michael F. Berger, Philippe L. Bedard, José Baselga, Alexander S. Baras, Monica Arnedos, Fabrice André
Supplemental Methods. Supplemental Table 1: ââ,¬â€¹Genomic Data Characterization by Center. Supplemental Table 2: ââ,¬â€¹Gene Panels Submitted by Each Center. Figure S1: Number of putative germline SNPs per sample, before and after
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d0898b4b793064fbee55cfdd12d0e9a
https://doi.org/10.1158/2159-8290.22531894.v1
https://doi.org/10.1158/2159-8290.22531894.v1